Böttcher MA, Held-Feindt J, Synowitz M, Lucius R, Traulsen A, Hattermann K. Modeling treatment-dependent glioma growth including a dormant tumor cell subpopulation. BMC Cancer. 2018 Apr 3;18(1):376. doi: 10.1186/s12885-018-4281-1. https://www.ncbi.nlm.nih.gov/pubmed/29614985

Flüh C, Chitadze G, Adamski V, Hattermann K, Synowitz M, Kabelitz D, Held-Feindt J. NKG2D ligands in glioma stem-like cells: expression in situ and in vitro. Histochem Cell Biol. 2018 Mar;149(3):219-233. doi: 10.1007/s00418-018-1633-5. Epub 2018 Jan 22. https://www.ncbi.nlm.nih.gov/pubmed/29356965

Adamski, V., Hempelmann, A., Flüh, C., Lucius, R., Synowitz, M., Hattermann, K., Held-Feindt, J. (2017): Dormant glioblastoma cells acquire stem cell characteristics and are differentially affected by Temozolomide and AT101 treatment. Oncotarget 8(64):108064-108078. Link